Molecular characteristics and tumorigenicity of ascites-derived tumor cells: mitochondrial oxidative phosphorylation as a novel therapy target in ovarian cancer.
OXPHOS
ascites
chemoresistance
metastasis
ovarian cancer
spheroids
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
16
04
2021
received:
27
11
2020
accepted:
28
05
2021
pubmed:
2
6
2021
medline:
8
4
2022
entrez:
1
6
2021
Statut:
ppublish
Résumé
Ovarian cancer disseminates primarily intraperitoneally. Detached tumor cell aggregates (spheroids) from the primary tumor are regarded as 'metastatic units' that exhibit a low sensitivity to classical chemotherapy, probably due to their unique molecular characteristics. We have analyzed the cellular composition of ascites from OvCa patients, using flow cytometry, and studied their behavior in vitro and in vivo. We conclude that ascites-derived cultured cells from OvCa patients give rise to two subpopulations: adherent cells and non-adherent cells. Here, we found that the AD population includes mainly CD90
Identifiants
pubmed: 34060699
doi: 10.1002/1878-0261.13028
pmc: PMC8637562
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3578-3595Informations de copyright
© 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
J Immunother Cancer. 2019 Jul 19;7(1):190
pubmed: 31324218
Br J Cancer. 2014 Feb 4;110(3):753-63
pubmed: 24322891
Clin Cancer Res. 2018 Jun 1;24(11):2482-2490
pubmed: 29420223
Int J Gynecol Cancer. 2019 Jan;29(1):140-146
pubmed: 30640696
Am J Transl Res. 2018 Oct 15;10(10):3086-3098
pubmed: 30416652
Oncogene. 2018 Sep;37(37):5127-5135
pubmed: 29789717
Gynecol Oncol. 2011 Nov;123(2):200-4
pubmed: 21802715
Gynecol Oncol. 2009 Apr;113(1):143-8
pubmed: 19135710
Gynecol Oncol. 2020 Jun;157(3):678-685
pubmed: 32317171
PLoS One. 2012;7(10):e46858
pubmed: 23056490
Int J Mol Sci. 2019 Jan 08;20(1):
pubmed: 30626133
Nat Commun. 2016 Mar 29;7:11150
pubmed: 27021436
Lancet. 2019 Mar 23;393(10177):1240-1253
pubmed: 30910306
Cell Metab. 2008 Jan;7(1):11-20
pubmed: 18177721
Int J Biochem Cell Biol. 2017 Nov;92:6-13
pubmed: 28888784
J Cancer Res Clin Oncol. 2013 Oct;139(10):1673-80
pubmed: 23942796
Nat Rev Dis Primers. 2016 Aug 25;2:16061
pubmed: 27558151
Cell Rep. 2016 May 31;15(9):2000-11
pubmed: 27210762
Science. 2017 May 5;356(6337):513-519
pubmed: 28473584
J Clin Invest. 2016 Nov 1;126(11):4157-4173
pubmed: 27721235
Clin Cancer Res. 2002 Mar;8(3):878-84
pubmed: 11895922
Genome Biol. 2020 Aug 26;21(1):216
pubmed: 32847614
Int J Cancer. 2001 Mar 20;95(2):121-7
pubmed: 11241323
Cell. 1995 Feb 24;80(4):603-9
pubmed: 7867067
Oncoimmunology. 2016 Oct 18;5(12):e1240857
pubmed: 28123876
Cancers (Basel). 2020 Mar 16;12(3):
pubmed: 32188032
J Pathol. 2008 Feb;214(3):357-67
pubmed: 18044827
Front Oncol. 2019 May 29;9:458
pubmed: 31192140
Pharmacol Rep. 2018 Jun;70(3):409-417
pubmed: 29627688
Anal Biochem. 2018 Jul 1;552:50-59
pubmed: 28711444
J Exp Med. 2019 Mar 4;216(3):688-703
pubmed: 30710055
Br J Cancer. 2010 May 25;102(11):1555-77
pubmed: 20502460
Exp Cell Biol. 1987;55(4):194-208
pubmed: 3678576
Int J Oncol. 2018 Jun;52(6):1899-1911
pubmed: 29620187
Front Cell Dev Biol. 2018 Jun 07;6:59
pubmed: 29930939
Histochem Cell Biol. 2020 May;153(5):367-377
pubmed: 32125512
Clin Cancer Res. 2017 Mar 1;23(5):1263-1273
pubmed: 27573169
J Hematol Oncol. 2018 Aug 23;11(1):107
pubmed: 30139373
Br J Cancer. 1991 May;63(5):711-4
pubmed: 2039697
Cancer. 2013 Feb 1;119(3):555-62
pubmed: 23208739
Nat Genet. 2016 Jul;48(7):758-67
pubmed: 27182968
Int J Cancer. 2009 Nov 15;125(10):2450-5
pubmed: 19670329
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Nat Rev Cancer. 2004 Jan;4(1):71-8
pubmed: 14708027
Front Cell Dev Biol. 2020 Aug 11;8:758
pubmed: 32850861
Genes Dev. 2005 Mar 1;19(5):570-82
pubmed: 15741319
Int J Cancer. 2014 Jan 1;134(1):32-42
pubmed: 23784932
Cancer Lett. 2012 Aug 28;321(2):137-43
pubmed: 22281241
J Ovarian Res. 2020 Sep 23;13(1):115
pubmed: 32967712
Int J Mol Med. 2019 Dec;44(6):2245-2255
pubmed: 31638162